Pangen Biotech Inc.
Founded in 2010 and KOSDAQ-listed in 2016, Pangen Biotech develops an EPO biosimilar and provides biopharmaceutical CDMO services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2016, Pangen Biotech is a biosimilar and biopharmaceutical CDMO company. Using its PanGen CHO-TECH™ technology, it sells an EPO biosimilar for anemia in chronic renal failure patients under the brand names Panpotin (Korea, Saudi Arabia, Thailand) and Erysaa (Malaysia, Philippines), and provides biopharmaceutical contract manufacturing (CMO) and development/technology transfer (CDO) services. The EPO biosimilar received marketing approvals in Malaysia (2019), Korea (2019), the Philippines (2022), Saudi Arabia (2023), and Thailand (2024), reaching five countries, and the company is also developing Factor VIII for hemophilia A, Aflibercept for macular degeneration and macular edema, an anti-SFTSV antibody, and G-CSF as a cancer treatment adjuvant.
Products & technology
- EPO biosimilar (Panpotin/Erysaa)Anemia treatment for chronic renal failure patients
- CDMO/CDO serviceContract development and manufacturing, and technology transfer for biopharmaceuticals including preclinical/clinical samples
Regulatory approvals
data.go.kr6 Korean MFDS drug approvals · 2018–2023
- MFDS drugPanpotin Prefilled Syringe 10000 IU (Epoetin alfa)2023-08-25Drug · Prescription · Approval202302526
- MFDS drugPanpotin Prefilled Syringe 6000 IU (Epoetin alfa)2023-08-25Drug · Prescription · Approval202302527
- MFDS drugPANPOTIN2019-11-28Drug · Prescription · Approval201908142
- MFDS drugPANPOTIN2019-11-28Drug · Prescription · Approval201908143
- MFDS drugERYSAA2018-04-04Drug · Prescription · Approval201801487
- MFDS drugERYSAA2018-04-04Drug · Prescription · Approval201801488
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2012–2021 (Phase 3 2 · Phase 1 2)
- Phase 3PGA40 주 250 IU, 500 IU, 1000 IU2021-09-17
1 trial site
- Phase 1PGA40 주 250 IU, 500 IU, 1000 IU2019-03-25
2 trial sites
- Phase 3PDA10 프리필드주 2000 IU2012-12-21
5 trial sites
- Phase 1PDA10 프리필드주 2000 IU2012-06-08
1 trial site
R&D and key agreements
Source: DART corporate disclosureFactor VIII · 혈우병A · Hemophilia A treatment
Aflibercept · 황반변성, 황반부종 · Treatment for macular degeneration and macular edema
항SFTSV항체 · 중증열성혈소판감소증후군(SFTS) · Treatment for severe fever with thrombocytopenia syndrome
G-CSF · 항암치료보조 · Cancer treatment adjuvant
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition